FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: LXX

  • Home
  •  | 
  • Tag Archives: "LXX"

Lexaria says TurboCBD increases CBD bioavailability

Lexaria says TurboCBD increases CBD bioavailability
Lexaria Bioscience Corp. has provided significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD -- a proprietary, DehydraTECH powered, cannabidiol (CBD) fortified hemp oil capsule developed by Lexaria. The degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers were studied.
Read more

Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages
Kelowna, British Columbia and Toronto, Ontario / TheNewswire / July 31, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP; CSE: LXX; the "Company" or "Lexaria"), a drug delivery platform innovator, and Hill Street Beverage Company Inc., (TSXV:BEER; "Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval. The Definitive Agreement is the conclusion of the process begun following the announcement of the non-binding letter of intent in April 2018. Terms of the Definitive Agreement were not disclosed.
Read more

Lexaria DehydraTECH Shows Promise in Nervous System Disorders

Lexaria DehydraTECH Shows Promise in Nervous System Disorders
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Biosciences Inc. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP), which originally developed its DehydraTECH™ platform to increase the bioavailability of cannabinoids. The company has since broadened its focus well-beyond the cannabis industry. A recent discovery suggests that the proprietary platform may be effective in enabling researchers to deliver APIs past the blood brain barrier. And, investors may want to take note of these developments.
Read more